![R. Session](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
R. Session
Direktor/Vorstandsmitglied bei
ReCode Therapeutics, Inc.
Profil
R.
A. Session was the founder of Taysha Gene Therapies, Inc. founded in 2019, where he held the title of Director from 2022 to 2023.
Currently, he holds the position of Director at Lung Therapeutics, Inc. since 2019, and Director at ReCode Therapeutics, Inc., Sandhill Therapeutics, Inc., and is a Member of the Society of Kauffman Fellows.
In the past, he worked as Senior Director-Strategic Planning & Finance at Reata Pharmaceuticals, Inc., Independent Director at Chardan Healthcare Acquisition 2 Corp., Vice President-Commercial Development at PTC Therapeutics, Inc. from 2013 to 2017, SVP-Corporate Strategy & Business Development at Novartis Gene Therapies, Inc. from 2017 to 2018, Chief Business Officer & Head-Corporate Strategy at 4D Molecular Therapeutics, Inc. in 2018, and Chief Business Officer at BridgeBio Pharma, Inc. from 2019 to 2020.
Mr. Session's education includes a graduate degree and an MBA from Texas A&M University and an undergraduate degree from The University of North Carolina at Charlotte.
Aktive Positionen von R. Session
| Unternehmen | Position | Beginn |
|---|---|---|
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage genetic medicines company that develops therapeutics for genetically defined diseases | Direktor/Vorstandsmitglied | - |
Sandhill Therapeutics, Inc.
 Sandhill Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops cellular immuno-oncology and cancer treatments | Direktor/Vorstandsmitglied | - |
Society of Kauffman Fellows
 Society of Kauffman Fellows Miscellaneous Commercial ServicesCommercial Services Operates as a network of venture capitalists | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von R. Session
| Unternehmen | Position | Ende |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Gründer | 02.03.2023 |
| BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 01.04.2020 |
| 4D MOLECULAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2018 |
| AVEXIS INC | Corporate Officer/Principal | 01.07.2018 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01.03.2017 |
Ausbildung von R. Session
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
59
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases | Health Technology |
Lung Therapeutics LLC
 Lung Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel pipeline of first-in-class medicines for fibrosis | Health Technology |
Texas A&M University
 Texas A&M University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Society of Kauffman Fellows
Society of Kauffman Fellows Miscellaneous Commercial ServicesCommercial Services Operates as a network of venture capitalists | Commercial Services |
The University of North Carolina at Charlotte
 The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
4D Molecular Therapeutics, Inc.
 4D Molecular Therapeutics, Inc. BiotechnologyHealth Technology Designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions | Health Technology |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage genetic medicines company that develops therapeutics for genetically defined diseases | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Chardan Healthcare Acquisition 2 Corp.
 Chardan Healthcare Acquisition 2 Corp. Financial ConglomeratesFinance Operates as blank check company | Finance |
Taysha Gene Therapies, Inc.
 Taysha Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes adeno-associated viruses-based gene therapies for the treatment of monogenic diseases of the central nervous system | Health Technology |
Sandhill Therapeutics, Inc.
Sandhill Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops cellular immuno-oncology and cancer treatments | Commercial Services |
